Immediate Laryngoscopy is Mandatory to Rule Out Progressive Disease
In a patient with HER2-positive metastatic cancer showing radiologic partial response but developing new hoarseness, you must perform urgent laryngoscopy to exclude laryngeal involvement by metastatic disease or recurrent laryngeal nerve involvement, as this represents a clinical-radiologic discordance that demands immediate investigation.
Critical Clinical Context
This scenario represents pseudoprogression versus true progression—the radiologic improvement does not align with new neurologic symptoms. Hoarseness in a cancer patient is a red flag that cannot be dismissed, regardless of imaging improvements elsewhere.
Immediate Diagnostic Approach
Perform laryngoscopy within days, not weeks 1. The key differential diagnoses include:
- Recurrent laryngeal nerve palsy from mediastinal/neck metastases (vocal cord paresis accounts for 2.8-8% of hoarseness cases) 1
- Direct laryngeal metastatic involvement (malignant tumors cause 2.2-3% of hoarseness) 1
- Leptomeningeal disease affecting cranial nerves
- Benign causes (less likely given oncologic context)
Do not empirically treat with antibiotics or corticosteroids—this is explicitly not recommended 1.
Management Algorithm Based on Laryngoscopy Findings
If Laryngoscopy Shows Metastatic Disease or Nerve Palsy:
Obtain brain MRI immediately 2. The ASCO guideline emphasizes having "a low threshold for performing diagnostic brain magnetic resonance imaging testing in the setting of any neurologic symptoms suggestive of brain involvement" 2.
Do NOT switch systemic therapy if extracranial disease is responding 2. The 2022 ASCO guideline specifically states: "For patients whose systemic disease is not progressive at the time of brain metastasis diagnosis, systemic therapy should not be switched from their current HER2-targeted therapy regimen" 2.
Consider local therapy options:
If Laryngoscopy Shows Benign Pathology:
- Voice therapy is first-line treatment (Level 1a evidence) 1, 4
- Address any contributing factors (reflux, voice overuse)
- Continue current oncologic regimen unchanged
Key Pitfalls to Avoid
Common Error #1: Assuming radiologic response means all disease is controlled. Clinical symptoms always trump imaging—this patient has clinical progression despite radiologic response.
Common Error #2: Delaying laryngoscopy. In cancer patients, especially with risk factors, hoarseness requires immediate laryngoscopic evaluation 1. Waiting 2-4 weeks for "watchful waiting" is inappropriate.
Common Error #3: Switching systemic therapy prematurely. If this represents isolated progression in one anatomic site while systemic disease responds, maintain the current HER2-targeted regimen and add local therapy 2.
Systemic Therapy Considerations
The current HER2-targeted regimen should be continued unless there is systemic (not just local) progression 2, 5. The 2018 ASCO guideline confirms that HER2-targeted therapy continues "until time of progression or unacceptable toxicities" 5.
If true systemic progression is confirmed, then escalate per standard algorithms (tucatinib-based regimens, trastuzumab deruxtecan) 2.
Documentation Requirements
Document the clinical-radiologic discordance explicitly. This affects:
- Clinical trial eligibility definitions
- Insurance authorization for treatment changes
- Multidisciplinary tumor board discussions
The bottom line: New neurologic symptoms in metastatic cancer patients demand immediate investigation regardless of favorable imaging elsewhere, and isolated anatomic progression does not mandate changing an otherwise effective systemic regimen.